Every FDA decision, PDUFA date, Phase 3 readout, and clinical milestone — ranked by Bio-Score™ predicted volatility magnitude. Updated daily.
A biotech catalyst is any scheduled or anticipated event that has the potential to significantly move a biotech company's stock price. The most impactful catalysts include FDA regulatory decisions (PDUFA dates), clinical trial data readouts (Phase 2/3 results), Advisory Committee (AdCom) votes, and new drug application (NDA/BLA) filings and decisions.
Unlike earnings reports in other sectors, biotech catalysts are often binary events — the drug either gets approved or it doesn't, the trial either succeeds or it fails. This binary nature creates outsized volatility, with stocks regularly moving 30-60% in a single session around major catalyst events.
BioCatalysts.AI tracks every upcoming catalyst and ranks them using the Bio-Score™ algorithm, which predicts the magnitude of expected volatility rather than the direction. Learn the key terminology or understand the confidence scorecard to get the most out of the catalyst feed.